ArticleAmerican journal of physiology. Renal physiology2018
SGLT2 inhibition in a kidney with reduced nephron number: modeling and analysis of solute transport and metabolism.
Article in American journal of physiology. Renal physiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed, 1 synthesis or guideline pooled it, 124 citations in OpenAlex.
- The impact of SGLT2 inhibitors on renal outcomes in patients with type 2 diabetes and chronic kidney disease: systematic review and meta-analysis.Frontiers in endocrinology · 2026Pooled it
- Pulmonary congestion relief by adding dapagliflozin to intravenous loop diuretic in acute heart failure patients.ESC heart failure · 2025Trial
- SGLT2 Inhibitors: Dual Effects on Erythropoiesis and Bone Metabolism.Journal of bone metabolism · 2026Review
- Transcriptomics of S3 segment in mice: response to type 1 diabetes, SGLT1/2 inhibition, or GLP1 receptor agonism.American journal of physiology. Renal physiology · 2026Article
- Article
- Combination of GLP-1 receptor agonists and SGLT2 inhibitors in cardiometabolic disease: synergistic, additive, or non-additive effects? A narrative review.Cardiovascular diabetology · 2026Review
- Empagliflozin and renal histological changes in an experimental model of heart failure in male rats.Physiological reports · 2026Article
- Sodium-Glucose Cotransporter 2 Inhibitors in Autosomal Dominant Polycystic Kidney Disease: Mechanistic Insights and Therapeutic Promise.Journal of the American Society of Nephrology : JASN · 2026Review
- Review
- ASK1 limits kidney glucose reabsorption, growth, and mid-late proximal tubule KIM-1 induction when diabetes and Western diet are combined with SGLT2 inhibition.American journal of physiology. Renal physiology · 2025Article
- Effects of sotagliflozin on kidney and cardiac outcome in a hypertensive model of subtotal nephrectomy in male mice.Physiological reports · 2025Article
- Genetic deletion of the kidney sodium/proton exchanger-3 (NHE3) does not alter calcium and phosphate balance due to compensatory responses.Kidney international · 2025Article
- State-of-the-Art-Review: Mechanisms of Action of SGLT2 Inhibitors and Clinical Implications.American journal of hypertension · 2024Review
- How can inhibition of glucose and sodium transport in the early proximal tubule protect the cardiorenal system?Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2024Review
- Nascent shifts in renal cellular metabolism, structure, and function due to chronic empagliflozin in prediabetic mice.American journal of physiology. Cell physiology · 2024Article
- How the kidney regulates magnesium: a modelling study.Royal Society open science · 2024Article
- Sex differences in renal transporters: assessment and functional consequences.Nature reviews. Nephrology · 2024Review
- Efficacy and Safety of Esaxerenone in Hypertensive Patients with Diabetes Mellitus Undergoing Treatment with Sodium-Glucose Cotransporter 2 Inhibitors (EAGLE-DH).Advances in therapy · 2023Article
- Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Nondiabetic Patients with Chronic Kidney Disease: A Review of Recent Evidence.Kidney diseases (Basel, Switzerland) · 2023Review
- Functional and Clinical Importance of SGLT2-inhibitors in Frailty: From the Kidney to the Heart.Hypertension (Dallas, Tex. : 1979) · 2023Review
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Sodium-glucose cotransporter 2 (SGLT2) inhibitors enhance urinary glucose, Na
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.